Meningococcal vaccine groups A C Y W-135 conjugate - Pfizer

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - Pfizer

Alternative Names: GSK 134612; MenACWY - GlaxoSmithKline; MenACWY conjugated vaccine - GlaxoSmithKline; MenACWY-TT; Nimenrix

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 19 Dec 2016 Registered for Meningococcal infections (In infants, In children, In adults) in European Union (IM)
  • 01 Oct 2015 GlaxoSmithKline completes a phase III trial in Meningococcal infections (In infants, Prevention) in Mexico and Lebanon (NCT01340898)
  • 01 Oct 2015 Pfizer acquires meningococcal vaccine groups A, C, Y, W-135 conjugate from GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top